Navigation Links
AMT Receives Orphan Drug Designation From the U.S. Food and Drug Administration Duchenne Muscular Dystrophy Gene Therapy
Date:9/24/2010

Drug Administration (FDA) has designated AMT-080, a gene therapy for Duchenne muscular dystrophy (DMD) as an orphan drug. In October 2009, the Committee for Orphan Medical Products of the European Medicines Agency granted AMT-080 orphan designation for the same indication in the European Union.

AMT has shown efficacy in studies of a preclinical model of DMD. These proof of concept studies demonstrated that AMT's technology resulted in functional dystrophin synthesis in both the heart and skeletal muscles, leading to the prevention of muscular dystrophy. These data are strengthened by a study in which this gene therapy approach was shown to successfully restore dystrophin activity in diseased human muscle cells obtained from biopsies of DMD patients. A Phase I/II clinical trial is scheduled to start by the end of 2012.

AMT has received an Innovation Credit of up to EUR 4 million from the Dutch government to support the development of AMT's gene therapy treatment for Duchenne Muscular Dystrophy (DMD). The credit is granted by SenterNovem, an agency of the Dutch Ministry of Economic affairs.

"It is exceptional that we have been able to reveal the promise of this therapy to the FDA in this early stage of the development. We believe our proven adenoassociated viral vector technology used in all our gene therapy products provides a distinct advantage. AMT has successfully conducted three clinical trials with its lead product Glybera that employs this technology, confirming that AAV-based delivery technology is safe and efficacious," noted Jörn Aldag, CEO of Amsterdam Molecular Therapeutics.

The FDA's orphan drug designation is intended to encourage research and development of new therapies for diseases that affect fewer than 200,000 U.S. residents. As a designated orphan drug, AMT-080 is eligible for tax credits based on its clinical development costs, as well as assistance from the FDA in guiding the drug through the regulatory
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Professor Leroux From ETH Receives the Debiopharm Life Sciences Award 2010
2. NephRx Corp. Receives Orphan Drug Designation for NX001 for Prevention of Delayed Kidney Graft Function
3. MabVax Therapeutics Receives Small Business Innovation Research Program Award from the National Cancer Institute
4. NanoSmart™ Pharmaceuticals, Inc. Receives Patent Allowance for Tumor Targeting Platform Technology
5. Renhuang Receives AAA(1) Rating from Chinese Academy of International Trade & Economic Cooperation of Ministry of Commerce
6. Keck Graduate Institute Receives $3.6 Million NIH Grant
7. MacroGenics Receives NIH Grant Funding of $9.8M for Three Projects; Funding Further Advances DART Platform and Infectious Disease Portfolio
8. IIVS Receives First Mark Twain Ethical Science Award for Successes In Replacing Animals for Chemical and Product Safety Testing
9. Sirnaomics Receives Two SBIR Grants from NIH for Developing siRNA Therapeutics to Treat Glioblastoma and Influenza Infection
10. China Agritech, Inc. Receives $10 Million From Warrant Exercise by The Carlyle Group
11. Chiasma Receives Orphan Drug Designation From the FDA for Octreolin™ for the Oral Treatment of Acromegaly
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... and RESEARCH TRIANGLE PARK, N.C. , ... ) announced today that Roger Jeffs , Ph.D., President ... overview and update on the company,s business at the Deutsche ... Boston, Massachusetts . The presentation will ... Eastern Time, and can be accessed via a live webcast ...
(Date:4/30/2015)... -- Roka Bioscience, Inc. (NASDAQ: ROKA ), a molecular ... the detection of foodborne pathogens, announced plans to release ... on May 7, 2015 after the close of the ... a conference call at 4:30 p.m. Eastern Time on ... results. During the conference call, material information concerning the ...
(Date:4/30/2015)... (PRWEB) April 30, 2015 Cytokinetics, Incorporated (Nasdaq: ... quarter of 2015 were $4.4 million, compared to $8.0 million ... for the first quarter was $8.9 million, or $0.23 per ... loss for the same period in 2014, of $8.7 million, ... March 31, 2015, cash, cash equivalents and investments totaled $117.5 ...
(Date:4/30/2015)... Nitto Avecia, a leading biotechnology manufacturer ... and production capability to serve biotechnology pharmaceutical clients. ... fulfillment continues to drive Nitto Avecia to enhance ... , In Fall 2014, Nitto Avecia ... at its Milford, MA facility, which is recognized ...
Breaking Biology Technology:Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2
... from around the world will present the latest breakthroughs ... at the 2008 Conference on Lasers and Electro-Optics/Quantum Electronics ... the San Jose McEnery Convention Center in San Jose, ... those in the lasers and electro-optics community. It will ...
... could be reduced by application of a simple polymer, ... injected into the blood stream as reported in ... , Andrew Koob and Richard Borgens from Purdue University, ... was effective in limiting damage if administered within four ...
... - Dragon Pharmaceutical Inc.,("Dragon Pharma" or the "Company" ... pharmaceutical company, today announced the results,of the Annual ... Shenzhen,China., There were 48,663,865 shares equaling 69.81% ... shareholders re-elected the following,eight persons to serve as ...
Cached Biology Technology:Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 2Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 3Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 4Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 5Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 6Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 7
(Date:4/10/2015)... April 10, 2015 Research and ... the "Security Competitive Profiles - NEC" report ... NEC will continue to supply a range ... market, with a company focus on the development of ... Winning opportunities in the Asia-Pacific ...
(Date:4/2/2015)... HAMBURG, Germany , April 2, 2015 /PRNewswire/ ... ten fingerprint tests DERMALOG by far outperforms the ... While always maintaining high accuracy, the system is ... second. Hence, the speed proves up to be ... 40% faster than its runner-up performance. ...
(Date:4/1/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces the second shipment ... underway to early access pre-order customers. ... retail outlets including Walmart, Target, AT&T, Dunkin, Donuts, Stop ... accepted at all outlets and very easy to use. ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4
... baggage may have helped a tiny fish thrive in ... UBC study published today in Science Express . ... originated in the ocean but began populating freshwater lakes ... past 20,000 years - a relatively short time span ...
... 2008 Presenting new research about national, home and ... a University of Houston professor and his colleagues has ... it comes to surveillance. Two professors ... fifth annual Institute of Electrical and Electronics Engineers International ...
... report reveals surprisingly large populations of two globally ... The report counted 42,000 black-shanked douc langurs along ... Biodiversity Conservation Area, an estimate that represents the ... world. WCS scientists conducted the surveys with the ...
Cached Biology News:'Armored' fish study helps strengthen Darwin's natural selection theory 2National security remedies among topics at surveillance confab 2National security remedies among topics at surveillance confab 3Unexpected large monkey population discovered 2
... is for when you need to make your ... transformation efficiency. Our services for preparing competent cells ... MCLab's custom competent cell service offers: ... Fast turnaround Quality control performance ...
SHEEP ANTI BOVINE LACTOPEROXIDASE...
FRACTALKINE [Human] (Recombinant)...
Growth Medium / Media...
Biology Products: